scholarly journals Delayed Hemolytic Transfusion Reaction in a Sickle Cell Disease Patient: A Case Report

Cureus ◽  
2020 ◽  
Author(s):  
Mohammed Saleh ◽  
Vishnu Priya Mallipeddi ◽  
Ahmed Ali
Keyword(s):  
Case Report ◽  
Sickle Cell Disease ◽  
Sickle Cell ◽  
Disease Patient ◽  
Sickle Cell Disease Patient ◽  
Transfusion Reaction ◽  
Cell Disease ◽  
Hemolytic Transfusion Reaction ◽  
Delayed Hemolytic Transfusion Reaction

scholarly journals Two Consecutive Episodes of Severe Delayed Hemolytic Transfusion Reaction in a Sickle Cell Disease Patient

2020 ◽  
Vol 2020 ◽  
pp. 1-5
Author(s):  
Clarisse Mpinganzima ◽  
Alf Haaland ◽  
Anne Guro Vreim Holm ◽  
Swee Lay Thein ◽  
Geir Erland Tjønnfjord ◽  
...  
Keyword(s):  
Sickle Cell Disease ◽  
Sickle Cell ◽  
Combined Treatment ◽  
Disease Patient ◽  
Transfusion Reaction ◽  
Cell Disease ◽  
Initial Surgery ◽  
Hemolytic Transfusion Reaction ◽  
Life Threatening ◽  
Delayed Hemolytic Transfusion Reaction

Patients with sickle cell disease (SCD) suffer from anemia and painful vaso-occlusive crisis (VOC) and sometimes need blood transfusions. Delayed hemolytic transfusion reaction (DHTR) is a rare life-threatening complication observed in SCD and mimics VOC. We describe a female SCD patient undergoing three surgical procedures during which DHTR developed following the first two. Prior to a planned tonsillectomy, she received transfusion and three days after surgery developed severe hemolysis as well as pain and respiratory symptoms. On suspicion of VOC, she received additional transfusions and became hemodynamically unstable, and her hemolytic anemia worsened. Gradually, she recovered and could be discharged after two weeks; DHTR was not suspected. Sixteen months later, an arthroplasty was performed due to avascular necrosis, and again she was transfused preoperatively. Similar to the initial surgery, she developed symptoms and signs of VOC after three days, but this time, DHTR was suspected and further transfusions were withheld. Although immunosuppressive medication did not alleviate the condition, she improved on combined treatment with darbepoietin, rituximab, and eculizumab. Six months later, a second arthroplasty was performed uneventfully after prophylaxis with rituximab and without transfusion. DHTR should be considered in the presence of severe, unexplained hemolysis following a recent transfusion, and additional transfusions in this setting should be given only on vital indication.

scholarly journals Rituximab for prevention of delayed hemolytic transfusion reaction in sickle cell disease

Haematologica ◽  
2007 ◽  
Vol 92 (12) ◽  
pp. e132-e135 ◽  
Author(s):  
F. Noizat-Pirenne ◽  
D. Bachir ◽  
P. Chadebech ◽  
M. Michel ◽  
A. Plonquet ◽  
...  
Keyword(s):  
Sickle Cell Disease ◽  
Sickle Cell ◽  
Transfusion Reaction ◽  
Cell Disease ◽  
Hemolytic Transfusion Reaction ◽  
Delayed Hemolytic Transfusion Reaction
Sign in / Sign up

Export Citation Format

Share Document